Achillion Pharmaceuticals (NASDAQ:ACHN) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02, Fidelity Earnings reports.
Shares of ACHN stock opened at $6.36 on Friday. The company has a market capitalization of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67. The company’s 50 day moving average price is $4.93 and its two-hundred day moving average price is $3.79. Achillion Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $6.46.
In related news, CEO Joseph Truitt sold 133,484 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the transaction, the chief executive officer now owns 103,734 shares of the company’s stock, valued at $660,785.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.58% of the company’s stock.
Several analysts have commented on the stock. JMP Securities downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. BidaskClub lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 12th. Svb Leerink lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $5.00 to $6.30 in a report on Friday, October 18th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 target price on the stock. in a report on Tuesday, August 27th. Finally, Leerink Swann lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 price objective on the stock. in a report on Friday, October 18th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $4.96.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Featured Article: Fundamental Analysis
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.